Last edition
News about "xevinapant plus chemoradiotherapy"
Merck Announces Update on Xevinapant Program in Locally Advanced Head and Neck Cancer
Merck has discontinued the Phase III randomized TrilynX study evaluating xevinapant plus chemoradiotherapy (CRT) in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
Xevinapant Plus Chemoradiotherapy | 27/06/2024 | By Aishwarya | 130
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members